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To stem the spiraling cost of cancer treatment, a concerted effort is urgently needed to develop 
molecular diagnostics to better identify the patients that respond to expensive targeted thera-
pies. Opportunities and obstacles in the development of such drug response biomarkers are 
discussed here.In the United States, approximately 30% 
of total health care costs for an indi-
vidual are incurred in the last year of life 
(Earle and Schrag, 2008). Terminal can-
cer patients with metastatic disease are 
treated with expensive “targeted” thera-
pies, often costing tens of thousands of 
dollars with minimal survival benefit. If 
we take the cost and clinical benefit of 
the epidermal growth factor receptor 
(EGFR) targeting drug cetuximab in lung 
cancer as a standard, it would cost $440 
billion to extend by one year the life of 
all Americans who die of cancer annually 
(Fojo and Grady, 2009). In the past, the 
pharmaceutical industry has predomi-
nantly been focused on the development 
of ever newer and better cancer drugs, 
without paying sufficient attention to the 
identification of the (often small) fraction 
of patients that respond to their drugs. 
It will require a disruptive innovation, a 
radically new approach to the way we 
diagnose and treat cancer, to stem the 
spiraling cost of care for cancer patients. 
A critical aspect of this more individual-
ized approach to cancer therapy will be 
the development of biological indica-
tors (biomarkers) that help identify those 
patients that are most likely to respond 
to these expensive therapies.
The Need for Biomarkers
We now understand why it is so hard to 
win the war on cancer. Cancer results 
from the sequential acquisition of a 
number of genetic alterations, and these 
mutations are often distinct in tumors 
that appear very similar when examined 
through conventional diagnostics. This 
molecular heterogeneity represents a 
major obstacle to the effective treat-
ment of cancer and requires the devel-opment of new classes of biomarkers 
to separate these apparently similar 
tumors into distinct subgroups that differ 
in response to therapy. There are three 
types of clinically relevant biomarkers: 
prognostic biomarkers (that predict 
disease outcome without further treat-
ment), predictive biomarkers (that fore-
tell response to a specific therapy), and 
pharmacodynamic biomarkers (that help 
decide on the optimal dose of a drug for 
an individual patient). A biomarker can 
be both prognostic and predictive, a 
good example being the estrogen recep-
tor in breast cancer. Estrogen receptor-
positive tumors have in general a more 
favorable outcome and are more often 
responsive to hormonal therapy. More-
over, if a biomarker identifies one group 
of patients having negligible risk of dis-
ease recurrence and a second group 
that has almost all of the risk of disease 
progression, obviously the latter group 
will also receive nearly all of the benefits 
of additional (adjuvant) therapy, yielding 
a combined prognostic/predictive bio-
marker.
There are only a few clinically useful 
biomarkers that predict the response 
of a cancer to conventional chemo-
therapy. However, it is likely that this 
is very different for biomarkers of 
response to the newer classes of “tar-
geted therapeutics”—drugs that specifi-
cally act on signaling pathways that are 
active in the cancer cell or the surround-
ing stroma. For instance, the analysis of 
cancer genotypes by selected sequenc-
ing of cancer genomes has identified 
strong correlations between the pres-
ence of the oncogenic BCR-ABL translo-
cation in leukemia and responses to the 
drug imatinib mesylate (see Review by A. CeNussenzweig and M.C. Nussenzweig on 
page 27 of this issue). Similarly, the pres-
ence of mutations in EGFR is correlated 
with responses to small-molecule inhibi-
tors of its activity. For a list of associa-
tions between genotypes and responses 
to kinase-inhibitory drugs, see Janne 
et al. (2009) and Sawyers (2008). Many 
of these relationships between genetic 
alterations and responses to drugs can 
be explained by “oncogene addiction”—
an acquired dependency of tumors on 
persistent signaling through a given 
activated signaling pathway—as sud-
den inhibition of this signaling by drug 
treatment can cause cell death (Wein-
stein and Joe, 2006). Such correlations 
between genotype and drug response 
are especially straightforward to identify 
when the mutant allele is either a direct 
target of the drug or a component of the 
signaling pathway targeted by the drug. 
A variety of methods are readily avail-
able for identifying structural alterations 
in genes of major signaling pathways, 
including next generation sequencing 
and comparative genomic hybridization 
(Pinkel and Albertson, 2005; Stratton et 
al., 2009). Biomarker discovery becomes 
challenging when there are no likely sus-
pects to consider. This is the case for 
antiangiogenic drugs, like bevacizumab, 
or for “multikinase” inhibitory drugs, like 
dasatinib, sorafenib, and sunitinib, for 
which it is often not clear which of the 
multiple targets is primarily responsible 
for their anticancer effects.
Tissue Is an Issue
Biomarkers of drug responsiveness are 
most readily discovered through analy-
sis of the tumor itself. There are at least 
three major obstacles in the discovery of ll 141, April 2, 2010 ©2010 Elsevier Inc. 13
Figure 1. Identification of Drug Response Biomarkers through Functional Genetic Screens
(A) Gain-of-function genetic screens. Collections of cDNAs are ectopically expressed in drug-sensitive 
cells, either in polyclonal format or in an arrayed format in multiwell plates, often through use of a viral 
vector system (retroviral, lentiviral, or adenoviral). Cells are exposed to a cancer drug and resistant cells 
will continue to proliferate. From drug-resistant colonies, cDNAs can be recovered, identified by se-
quence analysis, and retested for their ability to confer drug resistance.
(B) Short-hairpin RNA (shRNA) barcode loss-of-function genetic screens. Collections of shRNA vectors 
are expressed polyclonally in drug-sensitive cells and subjected to drug selection. Cells harboring an 
shRNA vector that confers drug resistance will become enriched in the population; shRNAs that enhance 
the sensitivity to a cancer drug will become depleted under drug selection compared to a reference 
population that is not exposed to drug. Each shRNA vector contains a unique identifier sequence (the 
barcode), which can be recovered by polymerase chain reaction (PCR) and its abundance quantified on 
a dedicated DNA microarray containing the barcode sequences. shRNAs that cause drug resistance are 
enriched and appear red on the microarray; depleted shRNAs appear green.drug response biomarkers from tumor 
tissue. The first relates to the preser-
vation of tumor tissue, which in most 
hospitals relies on formalin fixation and 
paraffin embedding (FFPE). Although 
this mode of tissue preservation is suit-
able for conventional routine diagnos-14 Cell 141, April 2, 2010 ©2010 Elsevier Inctics, such as microscopic grading (that 
is, determining the histological grade of 
the tumor) and immunohistochemistry, it 
severely affects the integrity of the RNA 
and (phospho)proteins that can serve as 
potential biomarkers of drug responses. 
Tissue collection in clinical trials is caught .in a “catch 22”: either one collects FFPE 
tissue, which is easy but restricts molec-
ular analysis of biomarkers, or one col-
lects fresh tissue, which provides more 
valuable material but may slow patient 
recruitment in community hospitals due 
to the more complex logistics. Cancer 
biomarker development will therefore not 
come of age until the value of fresh tis-
sue collection is engraved in the minds 
of a new generation of molecular pathol-
ogists. In the mean time, existing tech-
nologies can be optimized to extract as 
much relevant biomarker information as 
possible out of FFPE-fixed tissues (see, 
for example, Hoshida et al., 2008).
A second problem is that most early 
stage (phase II) clinical trials, in which 
biomarkers are typically discovered, 
enroll patients with metastatic disease. 
This often limits access to tumor tissue 
through biopsies due to the anatomical 
locations of the metastases. A potential 
solution is the use of noninvasive tech-
nologies to assess tumor biomarkers. 
For example, collecting circulating tumor 
cells can be an alternative to tissue 
biopsies, but the numbers of cells pres-
ent in the circulation is often very small 
(Pantel et al., 2009). Alternatively, tumor 
genotype can be assessed through the 
analysis of DNA in serum, which is shed 
by tumor cell lysis. The use of next gen-
eration sequencing may make it feasible 
to mine detailed information on copy 
number gains, losses, or mutations 
from analysis of tumor DNA in serum 
from cancer patients (Chiu et al., 2008; 
Thomas et al., 2007).
A third major factor limiting efficient 
biomarker discovery is access to suf-
ficient patient samples. An unbiased 
genome-wide search for association 
between gene expression and disease 
outcome requires at least 40 patients 
whose cancer responds to treatment 
and an equal number of nonresponders, 
as smaller sample sizes will lead to spu-
rious associations between gene activ-
ity and disease outcome. Most phase 
II clinical trials do not have sufficient 
drug responders to allow such unbiased 
biomarker discovery. There are several 
potential solutions to this problem. First, 
the number of patients in the trial can 
be greatly increased, which is time con-
suming and expensive. Alternatively, one 
can identify drug response signatures 
by correlating drug responsiveness of a 
large panel of cancer cell lines with their 
pattern of gene expression in vitro (Neve 
et al., 2006). However, it is too early to 
tell whether such in vitro-derived drug 
response signatures will have clinical 
utility. Finally, to minimize the chance of 
false associations, one can survey only 
a limited number of genes in the phase 
II clinical trial samples by preselecting 
candidate drug response biomarkers 
in appropriate preclinical models using 
functional genetics (see below).
Functional Genetic Screens for 
Biomarker Discovery
Many of the events that contribute to 
cancer pathogenesis are epigenetic 
rather than genetic. Such epigenetic 
modifications lead to alterations in gene 
expression and hence to changes in 
cellular behavior, including responses 
to cancer drugs. Important information 
about drug responses can therefore be 
gleaned from analysis of gene expression 
patterns in cancer (van’t Veer and Ber-
nards, 2008). But of these genes, which 
are critical determinants of responsive-
ness to a given cancer drug? As pointed 
out above, unbiased discovery by full 
genome surveys is often not an option 
because the tumor samples available are 
insufficient. Functional genetic screens 
in mammalian cells help to fill this gap.
The development of efficient tools to 
perform functional genetic screens in 
mammalian cells has enabled the dis-
covery of genes that play a critical part 
in specific cellular processes, includ-
ing responses to cancer drugs. Genetic 
screens, pioneered in model organisms, 
provide the most unbiased approach to 
identify genes that act in a biological 
process. Two types of genetic screen 
can be carried out in mammalian cells 
today. In “gain-of-function” screens sets 
of genes are ectopically expressed to 
ask which genes, when overexpressed, 
can modulate a biological process (Fig-
ure 1A). Conversely, RNA interference 
has enabled “loss-of-function” genetic 
screens in mammalian cells. In this type 
of screen, large sets of genes are either 
suppressed short term by synthetic 
small-interfering RNAs (siRNAs) or long 
term through vector-encoded shRNAs, 
and the effects on specific biological pro-
cesses are monitored. To find biomark-ers of drug responses, stable suppres-
sion of gene expression by short-hairpin 
RNAs (shRNAs) has the advantage that it 
allows the use of more physiological drug 
concentrations because drug responses 
can be monitored over longer periods 
of time. A particularly elegant iteration 
of the loss-of-function screen is the 
shRNA barcode screen, which enables 
the identification of all genes whose sup-
pression can cause alterations in drug 
responsiveness in a single experiment 
(Figure 1B). Because of the very nature 
of the genetic screens, the relationships 
between responses to cancer drugs 
and gene expression are causal rather 
than correlative (as is for instance the 
case when microarray analyses are per-
formed). Consequently, genes identified 
in genetic screens are strong candidates 
to foretell responses to the same drugs 
in the clinic.
Indeed, in several cases genetic 
screens have yielded drug response bio-
markers that could subsequently be vali-
dated in clinical samples from patients 
treated with the same drug. For instance, 
a shRNA barcode screen identified the 
tumor suppressor gene PTEN as a criti-
cal determinant of resistance of breast 
cancer to trastuzumab, an antibody that 
targets human epidermal growth factor 
receptor 2 (HER2). Subsequent analysis 
of some 50 tumor samples from patients 
treated with trastuzumab confirmed 
the clinical utility of the phosphatidyl-
inositol 3-kinase (PI3K)-PTEN pathway 
as a biomarker to predict trastuzumab 
responses in breast cancer (Berns et al., 
2007). Note that the number of tumor 
samples required for the initial clinical 
validation of this biomarker is typically 
available from a phase II trial. Similarly, 
a single-well siRNA screen targeting all 
known and putative kinases identified 
CDK10 as a gene whose suppression 
can confer resistance to the anti-hor-
monal drug tamoxifen in breast cancer 
cells. Here too, low CDK10 expression 
is associated with clinical resistance to 
tamoxifen (Iorns et al., 2008). Obviously, 
at this point such biomarkers are only 
candidates, which require validation in 
specifically designed prospective clini-
cal studies. A clinical trial to assess the 
validity of the PI3K pathway as a predic-
tor of the trastuzumab response is cur-
rently underway (Tomasello et al., 2008).CA relatively recent concept in the 
treatment of cancer is that of “synthetic 
lethality”—a situation in which a combi-
nation of two nonlethal mutations results 
in cell death (Hartwell et al., 1997). 
Synthetic lethality results from the fact 
that the acquisition of mutations also 
comes at a cost for the cancer cell, as 
the ability to respond to specific pertur-
bations may be affected when certain 
regulatory circuits have been rendered 
defective by mutation. Knowledge of 
synthetic lethal interactions can there-
fore provide insights into the “Achilles’ 
heel” of a cancer cell—the spot where 
hitting it with a targeted drug hurts the 
most. Loss-of-function genetic screens 
represent an excellent tool to identify 
such synthetic lethal interactions (Kae-
lin, 2005). Although most people will 
consider synthetic lethality to be useful 
to identify new classes of cancer drug 
targets, it can also be used to iden-
tify potential drug response biomark-
ers. In such chemical synthetic lethality 
screens, one searches for genes whose 
suppression increases the sensitivity of 
cells to a cancer drug. Perhaps the most 
salient example of a chemical synthetic 
lethal interaction, although not discov-
ered through a genetic screen, is the 
exquisite sensitivity of tumors harboring 
a BRCA1 or BRCA2 mutation to olaparib, 
a small-molecule inhibitor of poly [ADP]-
ribose polymerase (PARP) (Farmer et 
al., 2005; Fong et al., 2009). Knowledge 
of synthetic lethal interactions can also 
suggest powerful drug combinations if 
the pathway that is synthetic lethal with 
a drug can be inhibited by another drug. 
Thus, screening for genes that confer a 
synthetic lethal phenotype in combina-
tion with an experimental cancer drug 
may yield clues to the most responsive 
patient population.
Biomarkers of Pathway Activation
In many types of cancer, the same sig-
naling pathway is frequently targeted 
by mutation, but the components of 
the pathway that are mutated are not 
always the same. For instance, in breast 
cancer the PI3K-PTEN pathway can 
be activated by amplification of HER2, 
mutation of PIK3CA (the catalytic sub-
unit of phosphatidyl-inositol 3-kinase), 
loss of its antagonist PTEN, or mutation 
of AKT1, and additional mechanisms of ell 141, April 2, 2010 ©2010 Elsevier Inc. 15
activation of this pathway may yet exist. 
In colon cancer for instance, 70% of 
patients fail to respond to EGFR inhibi-
tory drugs, whereas only 30%–40% of 
this nonresponsiveness is explained by 
mutation of KRAS (Amado et al., 2008). 
It would therefore be beneficial to have 
“pathway activation biomarkers” that 
measure activation of a pathway, as 
such biomarkers do not require a com-
pete knowledge of all the possible ways 
in which a pathway can become acti-
vated during oncogenesis. Such path-
way activation markers can consist of 
phospho-specific antibodies that mea-
sure activation of a downstream compo-
nent of a signaling cascade, which can 
be measured in high throughput using 
protein lysate arrays (Spurrier et al., 
2008). Alternatively, pathway activation 
can be monitored by measuring the tran-
scriptional output of a signaling pathway, 
as activation of each pathway leads to a 
characteristic set of alterations in gene 
expression (Bild et al., 2006). Such path-
way activation signatures may have utility 
to guide the choice of therapy (Lee et al., 
2007; Potti et al., 2006). A potential com-
plication in using these pathway activa-
tion biomarkers is that they often cannot 
inform whether activation of the pathway 
results from an upstream event or from 
more downstream activation. The point 
at which a signaling pathway is activated 
can dramatically influence the response 
to a pathway-inhibitory drug. For 
instance, elevated levels of the ligands 
for EGFR predict favorable responses 
to EGFR antibody drugs in colon can-
cer, but downstream mutations in KRAS 
are associated with nonresponsive-
ness. Biomarkers of pathway activation 
may yield similar results in both cases 
(Amado et al., 2008; Khambata-Ford et 
al., 2007). Nevertheless, with pathway-
targeted therapy becoming increasingly 
used in cancer, the need to describe 
tumors by the pathways that drive the 
oncogenic process will increase accord-
ingly. Pathway activation biomarkers can 
play a crucial part in this transition.
Outlook
Historically, pharmaceutical companies 
have not been keen to develop biomark-
ers of drug responsiveness. A fear of 
reducing the market for their drugs by 
identifying a large fraction of patients 16 Cell 141, April 2, 2010 ©2010 Elsevier Incthat are unlikely to benefit from therapy 
has certainly been a factor. However, it 
is becoming increasingly evident that 
drug response biomarkers can also 
expand the number of eligible patients 
for a drug. For instance, inhibitors of the 
anaplastic leukemia kinase (ALK) show 
promise for the treatment of neuroblas-
tomas, as these tumors can carry ALK 
amplifications or mutations that activate 
ALK. Importantly, between 3% and 13% 
(depending on the populations studied) 
of non-small cell lung cancer (NSCLC) 
tumors harbor an EML4-ALK transloca-
tion, and in preclinical models it is partic-
ularly this group of NSCLCs that is also 
exquisitely sensitive to these ALK inhibi-
tors (Koivunen et al., 2008). Biomarkers 
of drug responsiveness are therefore not 
only a threat but also an opportunity for 
drug developers. Patients only stand to 
benefit from biomarkers, as biomarkers 
enable the selection of the most effec-
tive therapy upfront, sparing them the 
considerable toxicity associated with 
the conventional “trial and error” therapy 
choice.
Molecular diagnostics will increasingly 
be used to classify tumors according to 
the pathways that act as drivers of the 
oncogenic process rather than the tissue 
of origin. Such molecular tumor classi-
fication schemes will therefore be very 
helpful in selecting the appropriate path-
way inhibitor for the individual patient. 
Co-development of drugs together with 
a companion diagnostic that identifies 
the likely responders is the logical way 
forward. Such companion diagnostics 
are most quickly developed in neo-adju-
vant clinical trials, a setting in which the 
drug is given prior to surgery, as drug 
responses are almost immediately vis-
ible. Biomarker validation will be greatly 
helped by a new type of clinical trial, 
so-called “adaptive” trials. In such tri-
als, evidence is collected to either prove 
or disprove a given biomarker-driven 
hypothesis. Treatment regimens that 
show a high probability of being more 
effective than standard therapy will grad-
uate from the trial with their correspond-
ing biomarkers. Adaptive clinical trials 
like I-SPY2 for breast cancer will become 
the new paradigm for co-development 
of drugs and diagnostics (Barker et al., 
2009). Given that a poor biomarker can 
be just as bad for the patient as a bad .drug, the US Food and Drug Administra-
tion (FDA) has announced its intention to 
also regulate clinically used biomarkers. 
This will require a regulatory trajectory 
for biomarkers that is not too dissimilar 
from what is currently in place for drugs, 
including well-designed clinical studies 
and appropriate quality control. Devel-
opment of well-validated biomarkers 
will therefore take considerable effort, 
and most pharma companies currently 
lack the relevant expertise to do this. A 
tripartite partnership between pharma, 
biotech, and academia will be required 
to secure a more rapid transition to a 
more personalized treatment based on 
detailed insights into the specific defects 
of each individual cancer.
AcknowleDGmentS
I thank P. Borst and members of my laboratory for 
helpful discussions and comments on the manu-
script. The work of the author was supported by 
grants from the Centre of Biomedical Genetics, 
the Cancer Genomics Centre, the Netherlands Or-
ganisation for Scientific Research (NWO), and the 
Dutch Cancer Society.
ReFeRenceS
Amado, R.G., Wolf, M., Peeters, M., Van Cutsem, 
E., Siena, S., Freeman, D.J., Juan, T., Sikorski, R., 
Suggs, S., Radinsky, R., et al. (2008). J. Clin. On-
col. 26, 1626–1634.
Barker, A.D., Sigman, C.C., Kelloff, G.J., Hylton, 
N.M., Berry, D.A., and Esserman, L.J. (2009). Clin. 
Pharmacol. Ther. 86, 97–100.
Berns, K., Horlings, H.M., Hennessy, B.T., Ma-
diredjo, M., Hijmans, E.M., Beelen, K., Linn, S.C., 
Gonzalez-Angulo, A.M., Stemke-Hale, K., Haupt-
mann, M., et al. (2007). Cancer Cell 12, 395–402.
Bild, A.H., Yao, G., Chang, J.T., Wang, Q., Potti, 
A., Chasse, D., Joshi, M.B., Harpole, D., Lancast-
er, J.M., Berchuck, A., et al. (2006). Nature 439, 
353–357.
Chiu, R.W., Chan, K.C., Gao, Y., Lau, V.Y., Zheng, 
W., Leung, T.Y., Foo, C.H., Xie, B., Tsui, N.B., Lun, 
F.M., et al. (2008). Proc. Natl. Acad. Sci. USA 105, 
20458–20463.
Earle, C.C., and Schrag, D. (2008). Principles of 
health services research. In DeVita, Hellman and 
Rosenberg’s Cancer: Principles & Practice of 
Oncology, V. DeVita, T. Lawrence, and S. Rosen-
berg, eds. (Philadelphia, PA: Lippincott Williams & 
Wilkins), pp. 369–384.
Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N., 
Johnson, D.A., Richardson, T.B., Santarosa, M., 
Dillon, K.J., Hickson, I., Knights, C., et al. (2005). 
Nature 434, 917–921.
Fojo, T., and Grady, C. (2009). J. Natl. Cancer Inst. 
101, 1044–1048.
Fong, P.C., Boss, D.S., Yap, T.A., Tutt, A., Wu, P., 
Mergui-Roelvink, M., Mortimer, P., Swaisland, H., 
Lau, A., O’Connor, M.J., et al. (2009). N. Engl. J. 
Med. 361, 123–134.
Hartwell, L.H., Szankasi, P., Roberts, C.J., Mur-
ray, A.W., and Friend, S.H. (1997). Science 278, 
1064–1068.
Hoshida, Y., Villanueva, A., Kobayashi, M., Peix, 
J., Chiang, D.Y., Camargo, A., Gupta, S., Moore, 
J., Wrobel, M.J., Lerner, J., et al. (2008). N. Engl. J. 
Med. 359, 1995–2004.
Iorns, E., Turner, N.C., Elliott, R., Syed, N., Garrone, 
O., Gasco, M., Tutt, A.N., Crook, T., Lord, C.J., and 
Ashworth, A. (2008). Cancer Cell 13, 91–104.
Janne, P.A., Gray, N., and Settleman, J. (2009). 
Nat. Rev. Drug Discov. 8, 709–723.
Kaelin, W.G., Jr. (2005). Nat. Rev. Cancer 5, 
689–698.
Khambata-Ford, S., Garrett, C.R., Meropol, N.J., Basik, M., Harbison, C.T., Wu, S., Wong, T.W., 
Huang, X., Takimoto, C.H., Godwin, A.K., et al. 
(2007). J. Clin. Oncol. 25, 3230–3237.
Koivunen, J.P., Mermel, C., Zejnullahu, K., Murphy, 
C., Lifshits, E., Holmes, A.J., Choi, H.G., Kim, J., 
Chiang, D., Thomas, R., et al. (2008). Clin. Cancer 
Res. 14, 4275–4283.
Lee, J.K., Havaleshko, D.M., Cho, H., Weinstein, 
J.N., Kaldjian, E.P., Karpovich, J., Grimshaw, A., 
and Theodorescu, D. (2007). Proc. Natl. Acad. Sci. 
USA 104, 13086–13091.
Neve, R.M., Chin, K., Fridlyand, J., Yeh, J., Baeh-
ner, F.L., Fevr, T., Clark, L., Bayani, N., Coppe, J.P., 
Tong, F., et al. (2006). Cancer Cell 10, 515–527.
Pantel, K., Alix-Panabieres, C., and Riethdorf, S. 
(2009). Nat. Rev. Clin. Oncol. 6, 339–351.
Pinkel, D., and Albertson, D.G. (2005). Annu. Rev. 
Genomics Hum. Genet. 6, 331–354.
Potti, A., Dressman, H.K., Bild, A., Riedel, R.F., CeChan, G., Sayer, R., Cragun, J., Cottrill, H., Kel-
ley, M.J., Petersen, R., et al. (2006). Nat. Med. 12, 
1294–1300.
Sawyers, C.L. (2008). Nature 452, 548–552.
Spurrier, B., Ramalingam, S., and Nishizuka, S. 
(2008). Nat. Protoc. 3, 1796–1808.
Stratton, M.R., Campbell, P.J., and Futreal, P.A. 
(2009). Nature 458, 719–724.
Thomas, R.K., Baker, A.C., Debiasi, R.M., Winck-
ler, W., Laframboise, T., Lin, W.M., Wang, M., Feng, 
W., Zander, T., MacConaill, L., et al. (2007). Nat. 
Genet. 39, 347–351.
Tomasello, G., de Azambuja, E., Dinh, P., Snoj, N., 
and Piccart-Gebhart, M. (2008). Expert Rev. Anti-
cancer Ther. 8, 1883–1890.
van’t Veer, L.J., and Bernards, R. (2008). Nature 
452, 564–570.
Weinstein, I.B., and Joe, A.K. (2006). Nat. Clin. 
Pract. Oncol. 3, 448–457.ll 141, April 2, 2010 ©2010 Elsevier Inc. 17
